These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 12237630

  • 1. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
    Odunsi K, Ghamande S, Chandrasekaran EV, Ta A, Moysich KB, Driscoll D, Matta K, Lele S.
    Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F, Scaletta G, Capriglione S, Montera R, Luvero D, Lopez S, Gatti A, De Cicco Nardone C, Terranova C, Angioli R.
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [Abstract] [Full Text] [Related]

  • 4. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.
    Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Roxana I, Baselga J, Del Campo JM.
    Ann Oncol; 2008 Feb; 19(2):327-31. PubMed ID: 18065408
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N, Rauh-Hain JA, Shoni M, Berkowitz RS, Muto MG, Feltmate C, Schorge JO, Del Carmen MG, Matulonis UA, Horowitz NS.
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pretreatment CA 15-3 levels do not predict disease-free survival in patients with advanced epithelial ovarian cancer.
    Gemer O, Oustinov N, Gdalevich M, Dubnik S, Levy R, Yachnin A, Lavie O, Ben Baruch N, Ben Arie A.
    Tumori; 2013 May; 99(2):257-60. PubMed ID: 23748823
    [Abstract] [Full Text] [Related]

  • 10. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
    Son JH, Chang K, Kong TW, Paek J, Chang SJ, Ryu HS.
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA, Fagö-Olsen C, Høgdall E, Schnack TH, Christensen IJ, Nedergaard L, Lundvall L, Lydolph MC, Engelholm SA, Høgdall C.
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
    Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R.
    Int J Gynecol Cancer; 2016 Jan; 26(1):43-51. PubMed ID: 26588231
    [Abstract] [Full Text] [Related]

  • 15. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T, Li XP, Wang JL, Wang SJ, Wang Y, Sun XL, Cui H, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [Abstract] [Full Text] [Related]

  • 16. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T, Hynninen J, Auranen A, Matomäki J, Oksa S, Roering P, Grènman S.
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [Abstract] [Full Text] [Related]

  • 17. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
    Mathey S, Graeser MK, Zu Eulenburg C, Woelber L, Trillsch F, Jaenicke F, Müller V, Milde-Langosch K, Mahner S.
    Oncology; 2013 Feb; 85(2):69-77. PubMed ID: 23860180
    [Abstract] [Full Text] [Related]

  • 18. Uridine 5'-diphosphate-galactose:glycoprotein galactosyltransferase activity in the ovarian cancer patient.
    Bhattacharya M, Chatterjee SK, Barlow JJ.
    Cancer Res; 1976 Jun; 36(6):2096-101. PubMed ID: 57828
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer.
    Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppänen M, Grénman S.
    Int J Gynecol Cancer; 2011 Dec; 21(9):1573-8. PubMed ID: 21811175
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.